View Item 

Show simple item record

Abrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendation
dc.contributor.authorKim, Isaac E.
dc.contributor.authorJang, Thomas L.
dc.contributor.authorKim, Sinae
dc.contributor.authorModi, Parth K.
dc.contributor.authorSinger, Eric A.
dc.contributor.authorElsamra, Sammy E.
dc.contributor.authorKim, Isaac Yi
dc.date.accessioned2020-12-02T14:42:05Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-12-02T14:42:05Z
dc.date.issued2020-12-01
dc.identifier.citationKim, Isaac E.; Jang, Thomas L.; Kim, Sinae; Modi, Parth K.; Singer, Eric A.; Elsamra, Sammy E.; Kim, Isaac Yi (2020). "Abrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendation." Cancer 126(23): 5114-5123.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/163646
dc.publisherWiley Periodicals, Inc.
dc.subject.otherprostate cancer
dc.subject.otherprostate‐specific antigen
dc.subject.otherracial disparity
dc.subject.otherscreening
dc.subject.otherSurveillance Epidemiology and End Results (SEER)
dc.titleAbrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendation
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163646/2/cncr33179.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163646/1/cncr33179_am.pdfen_US
dc.identifier.doi10.1002/cncr.33179
dc.identifier.sourceCancer
dc.identifier.citedreferenceTsodikov A, Gulati R, Etzioni R. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2018; 168: 608 ‐ 609.
dc.identifier.citedreferenceSiegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69: 7 ‐ 34.
dc.identifier.citedreferenceRichard A, Rohrmann S, Zhang L, et al. Racial variation in sex steroid hormone concentration in black and white men: a meta‐analysis. Andrology. 2014; 2: 428 ‐ 435.
dc.identifier.citedreferenceBhardwaj A, Srivastava SK, Khan MA, et al. Racial disparities in prostate cancer: a molecular perspective. Front Biosci (Landmark Ed). 2017; 22: 772 ‐ 782.
dc.identifier.citedreferenceWallace TA, Prueitt RL, Yi M, et al. Tumor immunobiological differences in prostate cancer between African‐American and European‐American men. Cancer Res. 2008; 68: 927 ‐ 936.
dc.identifier.citedreferencePowell IJ, Dyson G, Land S, et al. Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomarkers Prev. 2013; 22: 891 ‐ 897.
dc.identifier.citedreferenceRose AE, Satagopan JM, Oddoux C, et al. Copy number and gene expression differences between African American and Caucasian American prostate cancer. J Transl Med. 2010; 8: 70.
dc.identifier.citedreferenceHardiman G, Savage SJ, Hazard ES, et al. Systems analysis of the prostate transcriptome in African‐American men compared with European‐American men. Pharmacogenomics. 2016; 17: 1129 ‐ 1143.
dc.identifier.citedreferenceJones RA, Steeves R, Williams I. How African American men decide whether or not to get prostate cancer screening. Cancer Nurs. 2009; 32: 166 ‐ 172.
dc.identifier.citedreferenceWoods VD, Montgomery SB, Belliard JC, Ramirez‐Johnson J, Wilson CM. Culture, black men, and prostate cancer: what is reality? Cancer Control. 2004; 11: 388 ‐ 396.
dc.identifier.citedreferenceCuevas AG, Trudel‐Fitzgerald C, Cofie L, Zaitsu M, Allen J, Williams DR. Placing prostate cancer disparities within a psychosocial context: challenges and opportunities for future research. Cancer Causes Control. 2019; 30: 443 ‐ 456.
dc.identifier.citedreferenceDess RT, Hartman HE, Mahal BA, et al. Association of black race with prostate cancer–specific and other‐cause mortality. JAMA Oncol. 2019; 5: 975 ‐ 983.
dc.identifier.citedreferenceRiviere P, Luterstein E, Kumar A, et al. Survival of African American and non‐Hispanic white men with prostate cancer in an equal‐access health care system. Cancer. 2020; 126: 1683 ‐ 1690.
dc.identifier.citedreferencePSA: prostate‐specific antigen, persisting scientific ambiguities. Harv Mens Health Watch. 2009; 13: 1 ‐ 6.
dc.identifier.citedreferenceMoyer VA; US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157: 120 ‐ 134.
dc.identifier.citedreferenceLu‐Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol. 2004; 171 ( 6 pt 1 ): 2285 ‐ 2290.
dc.identifier.citedreferenceFenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate‐specific antigen–based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018; 319: 1914 ‐ 1931.
dc.identifier.citedreferenceEtzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008; 19: 175 ‐ 181.
dc.identifier.citedreferenceSchroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow‐up. Lancet. 2014; 384: 2027 ‐ 2035.
dc.identifier.citedreferencevan Leeuwen PJ, Connolly D, Gavin A, et al. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer. 2010; 46: 377 ‐ 383.
dc.identifier.citedreferenceAndriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow‐up. J Natl Cancer Inst. 2012; 104: 125 ‐ 132.
dc.identifier.citedreferenceUS Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement [published correction appears in JAMA. 2018;319:2443]. JAMA. 2018; 319: 1901 ‐ 1913.
dc.identifier.citedreferenceDrazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate‐specific antigen–based screening. J Clin Oncol. 2015; 33: 2416 ‐ 2423.
dc.identifier.citedreferenceAhlering T, Huynh LM, Kaler KS, et al. Unintended consequences of decreased PSA‐based prostate cancer screening. World J Urol. 2019; 37: 489 ‐ 496.
dc.identifier.citedreferenceBlair BM, Robyak H, Clark JY, Kaag MG, Lehman EB, Raman JD. Impact of United States Preventive Services Task Force recommendations on prostate biopsy characteristics and disease presentation at a tertiary‐care medical center. Prostate Int. 2018; 6: 110 ‐ 114.
dc.identifier.citedreferenceEapen RS, Herlemann A, Washington SL 3rd, Cooperberg MR. Impact of the United States Preventive Services Task Force ‘D’ recommendation on prostate cancer screening and staging. Curr Opin Urol. 2017; 27: 205 ‐ 209.
dc.identifier.citedreferenceDinizo M, Shih W, Kwon YS, et al. Multi‐institution analysis of racial disparity among African‐American men eligible for prostate cancer active surveillance. Oncotarget. 2018; 9: 21359 ‐ 21365.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr33179_am.pdf
Size:
412.4KB
Format:
PDF
View/Open
Name:
cncr33179.pdf
Size:
334.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.